NCT02366949 is a Phase 1 clinical trial of BAY1217389 in Medical Oncology, sponsored by Bayer.

Who is sponsoring NCT02366949?

NCT02366949 is sponsored by Bayer.

What drugs are being tested in NCT02366949?

Interventions in NCT02366949: BAY1217389, Paclitaxel.

What condition does NCT02366949 study?

NCT02366949 studies Medical Oncology.

Is NCT02366949 still recruiting?

NCT02366949 is currently completed. Last updated 7 April 2020.

Last reviewed 2020-04-07 · How we verify

NCT02366949

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel

Completed Phase 1 Last updated 7 April 2020

What this trial tests

Phase 1 trial testing BAY1217389 in Medical Oncology in 75 participants. Completed in 18 April 2019.

Timeline

27 February 2015

Primary endpoint
30 March 2018

18 April 2019

Quick facts

Lead sponsor	Bayer
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	75
Start date	27 February 2015
Primary completion	30 March 2018
Estimated completion	18 April 2019
Sites	7 locations across Netherlands, United States

Drugs / interventions tested

BAY1217389 — full drug profile →
Paclitaxel — full drug profile →

Conditions studied

Medical Oncology — all drugs for Medical Oncology →

Sponsor

Bayer — full company profile →

Who can join

18 and older, any sex, with Medical Oncology. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of oral BAY1217389 given in combination with intravenous (IV) paclitaxel using an intermittent dosing schedule (2 days on / 5 days off) in subjects with advanced malignancies.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Tumour treating fields therapy for glioblastoma: current advances and future directions.
Rominiyi O, Vanderlinden A, Clenton SJ, Bridgewater C, et al · · 2021 · cited 203× · PMID 33144698 · DOI 10.1038/s41416-020-01136-5
Targeting the cell cycle in breast cancer: towards the next phase.
Thu KL, Soria-Bretones I, Mak TW, Cescon DW. · · 2018 · cited 117× · PMID 30078354 · DOI 10.1080/15384101.2018.1502567
Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel.
Scribano CM, Wan J, Esbona K, Tucker JB, et al · · 2021 · cited 107× · PMID 34516829 · DOI 10.1126/scitranslmed.abd4811
The two sides of chromosomal instability: drivers and brakes in cancer.
Hosea R, Hillary S, Naqvi S, Wu S, et al · · 2024 · cited 102× · PMID 38553459 · DOI 10.1038/s41392-024-01767-7
APC/C Dysfunction Limits Excessive Cancer Chromosomal Instability.
Sansregret L, Patterson JO, Dewhurst S, López-García C, et al · · 2017 · cited 96× · PMID 28069571 · DOI 10.1158/2159-8290.cd-16-0645
Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Mason JM, Wei X, Fletcher GC, Kiarash R, et al · · 2017 · cited 94× · PMID 28270606 · DOI 10.1073/pnas.1700234114
A link between mitotic defects and mitotic catastrophe: detection and cell fate.
Sazonova EV, Petrichuk SV, Kopeina GS, Zhivotovsky B. · · 2021 · cited 86× · PMID 34886882 · DOI 10.1186/s13062-021-00313-7
Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.
Thu KL, Silvester J, Elliott MJ, Ba-Alawi W, et al · · 2018 · cited 72× · PMID 29378962 · DOI 10.1073/pnas.1719577115

Verify or expand the search:

Other recruiting trials for Medical Oncology

Currently open trials in the same condition.

NCT06097533 — Improvement of Quality of Life by Cannabinoids in Oncologic Patients · Phase 2 · recruiting
NCT05359848 — A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemot · NA · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02366949 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 7 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02366949.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing